Shots:

• The P-IIb clinical trial involves evaluating the efficacy and safety of eliapixant (25/75/150mg- PO- bid) vs PBO in 300 patients with refractory chronic cough for 12wks.
• The trial met its 1EPs that showed an improvement in 24hrs. cough counts @12wks. of treatment. The results showed a favorable safety and tolerability profile of the therapy
• Eliapixant is a potent and selective P2X3 receptor antagonist. The therapy is currently being evaluated in P-II clinical trials for the treatment of endometriosis- overactive bladder- and neuropathic pain

 to   | Ref: Bayer | Image: Business Standard